<DOC>
	<DOCNO>NCT02759250</DOCNO>
	<brief_summary>To characterize safety profile ARGX-110 administer mono- combination therapy patient NPC various stage natural history ( adjuvant vs. metastatic ) .</brief_summary>
	<brief_title>A Study ARGX-110 Patients With Nasopharyngeal Carcinoma ( NPC )</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Age ≥18 year . Written inform consent prior studyrelated procedure Willing able comply protocolspecified procedure schedule evaluation Pathological diagnosis nasopharyngeal carcinoma ( NPC ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1or 2 Absolute neutrophil count ( ANC ) &gt; 0.5 x 109/L Haemoglobin &gt; 80 g/L Platelet count ≥ 50 x 109/L Total bilirubin ≤ 2 x upper limit normal ( ULN ) Alanine transaminase ( ALT ) ≤ 5 x ULN Serum creatinine ≤ 2 x ULN Exclusion criterion : History clinical evidence neoplastic central nervous system ( CNS ) involvement . Note : Irradiated brain metastasis stable &gt; 1 month require systemic glucocorticoid administration allow Major surgery within 4 week ARGX110 first dose administration Unresolved grade 3 4 toxicity prior therapy ( except mucositis local radiation therapy ) . Active , untreated viral , bacterial , systemic fungal infection Childbearing potential unless use adequate measure contraception Pregnancy lactation . History hypersensitivity recombinant proteins Any clinical finding , include psychiatric behavioural problem , , opinion Investigator , preclude patient safely participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>